Reported net loss of $57.5 million for Q3 2025 ended September 30, 2025, due to increased R&D expenses of $49.2 million.
Cash and cash equivalents rose to $272.6 million from $143.4 million at end of 2024, funded by $161.7 million public offering and $44.9 million ATM sales.
No collaboration revenue recorded, missing consensus estimate of $0.727 million; EPS of $(0.65) vs. consensus $(0.576).
Cash runway extends into 2027, supporting operations for at least 12 months.
IM-3050 Phase 1 trial initiation delayed to early 2026 from prior 2H 2025 guidance.
Announcement made on November 6, 2025 via 8-K filing with press release as Exhibit 99.1.